

# Guanidinoacetate Methyltransferase Deficiency

Subjects: Genetics & Heredity

Contributor: Camila Xu

Guanidinoacetate methyltransferase deficiency is an inherited disorder that primarily affects the brain and muscles.

Keywords: genetic conditions

---

## 1. Introduction

Without early treatment, people with this disorder have neurological problems that are usually severe. These problems include intellectual disability, speech development limited to a few words, and recurrent seizures (epilepsy). Affected individuals may also exhibit autistic behaviors that affect communication and social interaction or self-injurious behaviors such as head-banging. Other features of this disorder can include involuntary movements (extrapyramidal dysfunction) such as tremors or facial tics.

People with guanidinoacetate methyltransferase deficiency may have weak muscle tone and delayed development of motor skills such as sitting or walking. In severe cases they may lose previously acquired skills such as the ability to support their head or to sit unsupported.

## 2. Frequency

Guanidinoacetate methyltransferase deficiency is a very rare disorder. About 80 affected individuals have been described in the medical literature. Of these, approximately one-third are of Portuguese origin.

## 3. Causes

Mutations in the *GAMT* gene cause guanidinoacetate methyltransferase deficiency. The *GAMT* gene provides instructions for making the enzyme guanidinoacetate methyltransferase. This enzyme participates in the two-step production (synthesis) of the compound creatine from the protein building blocks (amino acids) glycine, arginine, and methionine. Specifically, guanidinoacetate methyltransferase controls the second step of this process. In this step, creatine is produced from another compound called guanidinoacetate. Creatine is needed for the body to store and use energy properly.

*GAMT* gene mutations impair the ability of the guanidinoacetate methyltransferase enzyme to participate in creatine synthesis, resulting in a shortage of creatine. The effects of guanidinoacetate methyltransferase deficiency are most severe in organs and tissues that require large amounts of energy, especially the brain.

### 3.1. The gene associated with Guanidinoacetate methyltransferase deficiency

- *GAMT*

## 4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

## 5. Other Names for This Condition

- creatine deficiency syndrome due to *GAMT* deficiency
- deficiency of guanidinoacetate methyltransferase

- GAMT deficiency

---

## References

1. Almeida LS, Vilarinho L, Darmin PS, Rosenberg EH, Martinez-Muñoz C, Jakobs C, Salomons GS. A prevalent pathogenic GAMT mutation (c.59G>C) in Portugal. *MolGenet Metab.* 2007 May;91(1):1-6.
2. Braissant O, Henry H, Béard E, Uldry J. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. *Amino Acids.* 2011May;40(5):1315-24. doi: 10.1007/s00726-011-0852-z.
3. Braissant O. GAMT deficiency: 20 years of a treatable inborn error of metabolism. *Mol Genet Metab.* 2014 Jan;111(1):1-3. doi:10.1016/j.ymgme.2013.11.002.
4. Béard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. *J Neurochem.* 2010 Oct;115(2):297-313. doi:10.1111/j.1471-4159.2010.06935.x.
5. Dhar SU, Scaglia F, Li FY, Smith L, Barshop BA, Eng CM, Haas RH, Hunter JV, Lotze T, Maranda B, Willis M, Abdenur J E, Chen E, O'Brien W, Wong LJ. Expanded clinical and molecular spectrum of guanidinoacetate methyltransferase (GAMT) deficiency. *Mol Genet Metab.* 2009 Jan;96(1):38-43. doi:10.1016/j.ymgme.2008.10.008.
6. El-Gharbawy AH, Goldstein JL, Millington DS, Vaisnins AE, Schlune A, Barshop BA, Schulze A, Koeberl DD, Young SP. Elevation of guanidinoacetate in newborn dried blood spots and impact of early treatment in GAMT deficiency. *Mol Genet Metab.* 2013 Jun;109(2):215-7. doi: 10.1016/j.ymgme.2013.03.003.
7. Gordon N. Guanidinoacetate methyltransferase deficiency (GAMT). *Brain Dev.* 2010 Feb;32(2):79-81. doi: 10.1016/j.braindev.2009.01.008. Review.
8. Mercimek-Mahmutoglu S, Ndika J, Kanhai W, de Villemeur TB, Cheillan D, Christensen E, Dorison N, Hannig V, Hendriks Y, Hofstede FC, Lion-Francois L, Lund AM, Mundy H, Pitelet G, Raspall-Chaure M, Scott-Schwoerer JA, Szakszon K, Valayannopoulos V, Williams M, Salomons GS. Thirteen new patients with guanidinoacetate methyltransferase deficiency and functional characterization of nineteen novel missense variants in the GAMT gene. *Hum Mutat.* 2014 Apr;35(4):462-9. doi: 10.1002/humu.22511.
9. Mercimek-Mahmutoglu S, Sinclair G, van Dooren SJ, Kanhai W, Ashcraft P, Michel OJ, Nelson J, Betsalel OT, Sweetman L, Jakobs C, Salomons GS. Guanidinoacetate methyltransferase deficiency: first steps to newborn screening for a treatable neurometabolic disease. *Mol Genet Metab.* 2012 Nov;107(3):433-7. doi:10.1016/j.ymgme.2012.07.022.
10. Nasrallah F, Feki M, Kaabachi N. Creatine and creatine deficiency syndromes: biochemical and clinical aspects. *Pediatr Neurol.* 2010 Mar;42(3):163-71. doi:10.1016/j.pediatrneurol.2009.07.015. Review.
11. Pasquali M, Schwarz E, Jensen M, Yuzyuk T, DeBiase I, Randall H, Longo N. Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency. *J Inher Metab Dis.* 2014 Mar;37(2):231-6. doi:10.1007/s10545-013-9662-7.
12. Stockler-Ipsiroglu S, van Karnebeek C, Longo N, Korenke GC, Mercimek-Mahmutoglu S, Marquart I, Barshop B, Grolik C, Schlune A, Angle B, Araújo HC, Coskun T, Diogo L, Geraghty M, Haliloglu G, Konstantopoulou V, Leuzzi V, Levtova A, Mackenzie J, Maranda B, Mhanni AA, Mitchell G, Morris A, Newlove T, Renaud D, Scaglia F, Valayannopoulos V, van Spronsen FJ, Verbruggen KT, Yuskiv N, Nyhan W, Schulze A. Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. *Mol Genet Metab.* 2014 Jan;111(1):16-25. doi:10.1016/j.ymgme.2013.10.018.
13. Stockler-Ipsiroglu S, van Karnebeek CD. Cerebral creatine deficiencies: a group of treatable intellectual developmental disorders. *Semin Neurol.* 2014 Jul;34(3):350-6. doi: 10.1055/s-0034-1386772. in: *Semin Neurol.* 2014 Sep;34(4):479.
14. Viau KS, Ernst SL, Pasquali M, Botto LD, Hedlund G, Longo N. Evidence-based treatment of guanidinoacetate methyltransferase (GAMT) deficiency. *Mol Genet Metab.* 2013 Nov;110(3):255-62. doi: 10.1016/j.ymgme.2013.08.020.